Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease

NCT00082602 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: galantamine ER

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]